<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215965</url>
  </required_header>
  <id_info>
    <org_study_id>2019-52</org_study_id>
    <nct_id>NCT04215965</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a Citrate-based Anticoagulation With Calcium-free Phosphate-containing Fluid in Renal Replacement Therapy</brief_title>
  <acronym>Phosphorus</acronym>
  <official_title>Efficacy and Safety of a Low-citrate-based Anticoagulation With Calcium-free Phosphate-containing Replacement Fluid Compared to Standard Citrate-based Anticoagulation Protocol in Patients Requiring Continuous Renal Replacement Therapy; a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present prospective multicenter RCT we will evaluate the effects on efficacy,
      acid-base status and serum phosphate levels of a new RCA protocol for Continuous Venovenous
      Hemodiafiltration (CVVHDF) using an 18 mmol/l citrate solution in combination with a
      calcium-free phosphate-containing solution, acting as dialysate and replacement fluid. The
      new protocol will be introduced with the following targets: a) to refine buffers balance of a
      previously adopted RCA protocol for Continuous Venovenous Hemofiltration (CVVH), based on a
      18 mmol/l citrate solution (Regiocit) combined with calcium and phosphate-free dialysate
      fluid (PrismOcal B22) and a conventional phosphate-containing replacement fluid (Phoxilium)
      to prevent CRRT-related phosphate depletion
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circuit lifetime</measure>
    <time_frame>First 3 days of continous renal replacempent therapy</time_frame>
    <description>Number of minutes lifespan circuit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the new RCA solution</measure>
    <time_frame>first 3 days of CRRT</time_frame>
    <description>Mean daily delivered RRT dose during the first 3 days of CRRT in ml/kg/h between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the new RCA solution</measure>
    <time_frame>first 3 days of CRRT</time_frame>
    <description>Percentage of decreasing urea during CRRT course between two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Critical Care</condition>
  <arm_group>
    <arm_group_label>Experimental Standard citrate protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CVVHDF will be performed using Regiocit solution in the predilution mode, Biphozyl in the dialysate and postdilution mode. CRRT will be started at a dose of 35 ml/kg/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventionnal citrate protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CVVHDF will be performed using Regiocit solution in the predilution mode, Prismocal B22 (calcium and phosphate free) in the dialysate mode, and Phoxilium in the postdilution mode. CRRT will be started at a dose of 35 ml/kg/h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biphozyl (dialysate and replacement)</intervention_name>
    <description>Replacement solution with phosphate and without calcium in CRRT with citratre-based antigoagulation</description>
    <arm_group_label>Experimental Standard citrate protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prismocal B22 (dialysate) + phoxilium (replacement)</intervention_name>
    <description>solution with phosphate and calcium in CRRT with citratre-based antigoagulation</description>
    <arm_group_label>Conventionnal citrate protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute renal failure requiring CRRT

          2. Suitability for regional anticoagulation of the CRRT circuit

          3. Clinical equipoise regarding the method of circuit anticoagulation

          4. Subject is affiliated with a social security system (if required by individual country
             regulations).

          5. Subject meets national regulatory criteria for clinical trial participation.

          6. Subject or subject's Legally Authorized Representative (LAR) has signed the study
             Informed Consent form

        Exclusion Criteria:

          1. Age less than 18 years

          2. Expected stay in ICU less than 24 hours

          3. Pregnant or breastfeeding

          4. Suspected ischemic hepatitis or liver failure

          5. Chronic kidney disease requiring dialysis prior to ICU admission

          6. As applicable by French law, subject who is a protected individual such as an
             incompetent adult or incarcerated person

          7. Metformin and acethaminophen intoxication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie GARRIDO</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lionel VELLY, MD/PhD</last_name>
    <email>lionel.velly@ap-hm.fr</email>
  </overall_contact>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRRT</keyword>
  <keyword>Renal failure</keyword>
  <keyword>Citrate</keyword>
  <keyword>Phosphore</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

